Journal of Clinical Oncology
Articles in this Issue
Survival and prognostic factors of patients with Ewing sarcoma at first recurrence following modern era multimodal therapy: A report from the Children’s Oncology Group (COG).
10035 Background: Ewing sarcoma (EwS) is a rare malignancy of children, adolescents and young adults for which outcomes have progressively improved throug...
Ethnic disparities in clinical trials for FDA-approved drugs in breast cancer: A post-COVID era analysis (2020-2024).
e13759 Background: Despite advances in cancer treatment, racial and ethnic minorities remain significantly underrepresented in cancer research, particular...
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
1001 Background: Imlunestrant (imlu) is a next-generation, brain-penetrant, oral selective estrogen receptor degrader. The EMBER-3 trial, in patients (pts...
A novel staging system for cancer cachexia.
12073 Background: Cancer cachexia affects a large percentage of advanced cancer patients. It’s defined by a consensus definition of unintentional >5% b...
A phase II study of tumor microenvironment profiling at single cell level in patients with locally advanced cervical cancer (LACC) treated with immunotherapy combined with concurrent chemoradiotherapy (CICRT).
5518 Background: Concurrent chemoradiotherapy (CCRT) followed by intrauterine brachytherapy is the standard treatment for LACC, while the therapeutic effi...
Predictors of adherence to an on/off regimen for lenalidomide in patients with multiple myeloma.
e19546 Background: The objective of this work was to evaluate the predictors of adherence to lenalidomide, taken in successive 21-day/7-day on/off cycles....
Cancer risk of pathogenic germline variants among 164,774 adult cancers.
10511 Background: Pathogenic germline variants (PGV) in cancer-predisposition genes influence the development of many cancer types but our understanding o...
Patient-generated health DATA as a risk stratification tool: Real-world multidisciplinary care study from a developing-country private clinic.
e23342 Background: Oncological care development usually results in significantly increased costs, causing difficult incorporation by low-income and/or und...
<i>SPOP</i> mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI).
e17082 Background: Inactivating missense mutations in the tumor suppressor gene speckle-type pox virus and zinc finger protein (SPOP) occur in up to 15% o...
Overall survival in metastatic castration-resistant prostate cancer (mCRPC): A retrospective electronic medical record analysis of men treated with sipuleucel-T in community urology over 14 years.
e17041 Background: Treating mCRPC remains challenging, with limited options for prolonging overall survival (OS). Sipuleucel-T, an autologous prostate-spe...
A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.
2004 Background: Asandeutertinib (TY-9591), a deuterated osimertinib derivative, is a new central nervous system-active 3rd generation epidermal growth fa...
Circulating mitochondrial proteins as plasma biomarkers for chromophobe renal cell carcinoma.
e16527 Background: Chromophobe renal cell carcinoma (ChRCC) is the second most common subtype of non-clear cell renal cell carcinoma. Arising from the mit...
Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer.
1045 Background: Trastuzumab Deruxtecan (T-DXd) is a HER2-targeting antibody drug conjugate approved for the treatment of HER2 low metastatic breast cance...
A single institution study evaluating the fertility of young adults with malignancy treated with immunotherapy and early referral to oncofertility providers.
e23254 Background: Immune checkpoint inhibitors (ICIs) are used among multiple types of cancers. However, there are limited studies on the long-term effec...
Development and implementation of a home bortezomib injection program in the US (Ann Arbor VA Close to Me).
e13559 Background: Veterans in Michigan, northwestern Ohio, and northern Indiana have only two Veterans Health Association (VHA) facilities available that...
Representation in clinical trials evaluating lifestyle interventions targeting energy balance in cancer survivors: A scoping review.
e23017 Background: The rate of clinical trial participation in any cancer research study is 22%, with 7% in cancer treatments (drug, devices, behavior). H...
CA209-8TY trial, a randomized phase 2 trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.
5018 Background: Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer related mortality in men worldwide. Treatme...
Inclusion of people living with HIV in Food and Drug Administration (FDA) oncology pivotal registration trials from 2020 to 2024.
1517 Background: People living with HIV (PLWH) have an increased risk of developing cancers compared to the population without HIV, with cancer being the...
Comparison of different induction therapy for locally advanced marginal resectable and unresectable esophageal squamous cell carcinoma and the prognostic value of subsequent conversion surgery: A real world study.
e16073 Background: The prognosis of locally advanced borderline resectable esophageal squamous cell carcinoma (BR-ESCC) and unresectable esophageal squamo...
Efficacy and safety analysis of adjuvant atezolizumab in non-small cell lung cancer patients in China: A single center retrospective analysis.
e20007 Background: Atezolizumab after adjuvant chemotherapy has become a promising treatment option for patients with resected early-stage NSCLC. We aimed...
Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.
5561 Background: As the use of PARPi increases in high-grade serous ovarian cancer (HGSOC) resistance mechanisms ultimately arise. Emerging therapeutic st...
WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.
7005 Background: Outcomes for patients relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) remain poor. Zilovertamab vedotin (ZV) is a novel R...
Association of neighborhood-level factors with access to genetic testing in patients with resectable pancreatic ductal adenocarcinoma.
4196 Background: Since 2019, the NCCN has recommended genetic testing for all patients with pancreatic ductal adenocarcinoma (PDAC). However, only one-thi...
Role of high-dose vitamin C as adjunct treatment in gastric and colorectal cancers: A systematic review.
e15567 Background: Ascorbic acid (Vitamin C), a potent antioxidant, has shown promise in cancer treatment, particularly for colorectal cancer (CRC) and ga...
Factors influencing withdrawal without a defined reason in oncology trials.
e23014 Background: Withdrawal without a defined reason (WWDR) undermines the reliability and interpretability of clinical trial results and poses a critic...